CA2621088A1 - Genetically engineered fowlpox-based vaccine strain - Google Patents
Genetically engineered fowlpox-based vaccine strain Download PDFInfo
- Publication number
- CA2621088A1 CA2621088A1 CA002621088A CA2621088A CA2621088A1 CA 2621088 A1 CA2621088 A1 CA 2621088A1 CA 002621088 A CA002621088 A CA 002621088A CA 2621088 A CA2621088 A CA 2621088A CA 2621088 A1 CA2621088 A1 CA 2621088A1
- Authority
- CA
- Canada
- Prior art keywords
- virus
- recombinant
- vaccine
- recombinant virus
- poxvirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract 10
- 208000000666 Fowlpox Diseases 0.000 title claims 2
- 241000700605 Viruses Species 0.000 claims abstract 16
- 241000712461 unidentified influenza virus Species 0.000 claims 3
- 241000711404 Avian avulavirus 1 Species 0.000 claims 2
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 claims 1
- 241000701931 Canine parvovirus Species 0.000 claims 1
- 241000193449 Clostridium tetani Species 0.000 claims 1
- 241000725619 Dengue virus Species 0.000 claims 1
- 241000230501 Equine herpesvirus sp. Species 0.000 claims 1
- 241000283073 Equus caballus Species 0.000 claims 1
- 108091029865 Exogenous DNA Proteins 0.000 claims 1
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 claims 1
- 241000714165 Feline leukemia virus Species 0.000 claims 1
- 241000150562 Hantaan orthohantavirus Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims 1
- 241000710842 Japanese encephalitis virus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 241000711386 Mumps virus Species 0.000 claims 1
- 241000711798 Rabies lyssavirus Species 0.000 claims 1
- 241000713311 Simian immunodeficiency virus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 208000009305 pseudorabies Diseases 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 abstract 4
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 230000007923 virulence factor Effects 0.000 abstract 2
- 239000000304 virulence factor Substances 0.000 abstract 2
- 241000178270 Canarypox virus Species 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
What is described is a modified vector, such as a recombinant poxvirus, particularly recombinant canary poxvirus, having enhanced safety. The modified recombinant virus has nonessential virus-encoded genetic functions inactivated therein so that virus has attenuated virulence.
In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor.
In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
In one embodiment, the genetic functions are inactivated by deleting an open reading frame encoding a virulence factor.
In another embodiment, the genetic functions are inactivated by insertional inactivation of an open reading frame encoding a virulence factor. What is also described is a vaccine containing the modified recombinant virus having nonessential virus-encoded genetic functions inactivated therein so that the vaccine has an increased level of safety compared to known recombinant virus vaccines.
Claims (9)
1. A recombinant virus, comprising exogenous DNA from a non-poxvirus source and encoding an antigenic protein of the source inserted by recombination in a nonessential region of a fowlpox genome, wherein the non-poxvirus source is rabies virus, Hepatitis B virus, Japanese encephalitis virus, yellow fever virus, Dengue virus, measles virus, pseudorabies varius, Epstein-Barr virus, herpes simplex virus, human immunodeficiency virus, simian immunodeficiency virus, equine herpes virus, bovine herpes virus, bovine viral diarrhea virus, human cytomegalovirus, canine parvovirus, equine influenza virus, feline leukemia virus, feline herpes virus, Hantaan virus, C. tetani, avian influenza virus, mumps virus, or Newcastle Disease virus.
2. The recombinant virus as claimed in claim 1, wherein the non-poxvirus source is avian influenza virus and the recombinant virus is vFP89, vFP92, vFP100 or vFP122.
3. The recombinant virus as claimed in claim 1, wherein the non-poxvirus source is human immunodeficiency virus and the recombinant virus is vFP62, vFP63 or vFP174.
4. The recombinant virus as claimed in claim 1, wherein the non-poxvirus source is Newcastle Disease virus and the recombinant virus is vFP96.
5. The recombinant virus as claimed in claim 1, which is vFP62 or vFP63.
6. The recombinant virus as claimed in claim 1, which is vFP89, vFP92, vFP100, or vFP122.
7. A vaccine for inducing an immunological response in a host animal inoculated with the vaccine, said vaccine comprising a carrier and the recombinant virus as claimed in any one of claims 1 to 6.
8. A vaccine for inducing an immunological response in a human inoculated with the vaccine, said vaccine comprising a carrier and the recombinant virus as claimed in any one of claims 1 to 6.
9. A method for expressing an antigenic protein in a cell cultured in vitro, which method comprises introducing into the cell the recombinant virus as claimed in any one of claims 1 to 6.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66605691A | 1991-03-07 | 1991-03-07 | |
| US666,056 | 1991-03-07 | ||
| US71396791A | 1991-06-11 | 1991-06-11 | |
| US713,967 | 1991-06-11 | ||
| US84795192A | 1992-03-06 | 1992-03-06 | |
| US847,951 | 1992-03-06 | ||
| CA002558659A CA2558659C (en) | 1991-03-07 | 1992-03-09 | Genetically engineered canary poxvirus-based vaccine strain |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002558659A Division CA2558659C (en) | 1991-03-07 | 1992-03-09 | Genetically engineered canary poxvirus-based vaccine strain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2621088A1 true CA2621088A1 (en) | 1992-09-17 |
| CA2621088C CA2621088C (en) | 2010-11-02 |
Family
ID=39326037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2621088A Expired - Lifetime CA2621088C (en) | 1991-03-07 | 1992-03-09 | Genetically engineered fowlpox-based vaccine strain |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2621088C (en) |
-
1992
- 1992-03-09 CA CA2621088A patent/CA2621088C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2621088C (en) | 2010-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Roberts et al. | Vaccination with a recombinant vesicular stomatitis virus expressing an influenza virus hemagglutinin provides complete protection from influenza virus challenge | |
| Baxby et al. | Potential use of non-replicating vectors as recombinant vaccines | |
| DK0550553T3 (en) | Viral defective vaccine made from a trans-complementing cell line | |
| Dietzschold et al. | New approaches to the prevention and eradication of rabies | |
| WO2001091536A3 (en) | Genetic vaccine that mimics natural viral infection and induces long-lasting immunity to pathogens | |
| KR920700289A (en) | Herpesvirus Recombinant Smallpox Virus Vaccine | |
| DK0500917T3 (en) | Vaccines and methods based on recombinant herpes simplex viruses. | |
| KR880700070A (en) | Virus Waxin | |
| EP0584348A4 (en) | Genetic vaccine for immunodeficiency viruses | |
| RU2001110116A (en) | RNA expression systems of recombinant Newcastle disease virus and vaccine | |
| HRP20190525T4 (en) | Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof | |
| CA2031164A1 (en) | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof | |
| EP0261940A3 (en) | Pseudorabies vaccines and dna vectors for recombination with pox viruses | |
| Zivcec et al. | The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies | |
| SG55095A1 (en) | Viruses and their use as a vaccine against feline infectious peritonitis virus disease | |
| Carossino et al. | Novel vaccination approaches against equine alphavirus encephalitides | |
| JPH06500096A (en) | A method for modifying the cell, tissue or host tropism of a microorganism, the recombinant microorganism obtained by this method and the use of the recombinant microorganism in medicine and veterinary medicine. | |
| CA2621088A1 (en) | Genetically engineered fowlpox-based vaccine strain | |
| ATE102650T1 (en) | MUTANTS OF INFECTIOUS BOVIN RHINOTRACCHIE VIRUS, VACCINE CONTAINING THEM, METHODS FOR THEIR PRODUCTION AND THEIR USE. | |
| EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
| CA2166406A1 (en) | Recombinant swinepox virus | |
| WO1994000586A3 (en) | Infectious bovine rhinotracheitis virus mutants and vaccines | |
| DK0606452T3 (en) | Vector vaccines from recombinant cat herpes virus | |
| Sheppard | Viral vectors for veterinary vaccines | |
| Brun | An overview of veterinary viral diseases and vaccine technologies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |